{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:35:59Z","timestamp":1790789759901,"version":"4.1.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022817","name":"Lanzhou University Second Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022817","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017702","name":"Innovation and Entrepreneurship Talent Project of Lanzhou","doi-asserted-by":"publisher","award":["2020-RC-48"],"award-info":[{"award-number":["2020-RC-48"]}],"id":[{"id":"10.13039\/501100017702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.gendis.2022.03.004","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T05:37:58Z","timestamp":1648445878000},"page":"2306-2319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations"],"prefix":"10.1016","volume":"10","author":[{"given":"Tao","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Gang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-Sheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6735","key":"10.1016\/j.gendis.2022.03.004_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/20974","article-title":"Structure and ligand of a histone acetyltransferase bromodomain","volume":"399","author":"Dhalluin","year":"1999","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.gendis.2022.03.004_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.gendis.2022.03.004_bib3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","article-title":"The BET family in immunity and disease","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.gendis.2022.03.004_bib5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1039\/C8MD00198G","article-title":"Targeting Brd4 for cancer therapy: inhibitors and degraders","volume":"9","author":"Duan","year":"2018","journal-title":"Medchemcomm"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nsmb.3228","article-title":"BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin","volume":"23","author":"Devaiah","year":"2016","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol Cancer"},{"issue":"24","key":"10.1016\/j.gendis.2022.03.004_bib8","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1073\/pnas.1919507117","article-title":"MYC protein stability is negatively regulated by BRD4","volume":"117","author":"Devaiah","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"19","key":"10.1016\/j.gendis.2022.03.004_bib9","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1158\/0008-5472.CAN-19-0442","article-title":"BRD4 promotes gastric cancer progression and metastasis through acetylation-dependent stabilization of snail","volume":"79","author":"Qin","year":"2019","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.molcel.2020.04.034","article-title":"Opposing functions of BRD4 isoforms in breast cancer","volume":"78","author":"Wu","year":"2020","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13073-020-00760-3","article-title":"ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer","volume":"12","author":"Szczepanski","year":"2020","journal-title":"Genome Med"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib12","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.gendis.2022.03.004_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.semcancer.2017.09.001","article-title":"Epigenetics in pediatric acute lymphoblastic leukemia","volume":"51","author":"Nordlund","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib14","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","article-title":"Targeting MYC in multiple myeloma","volume":"32","author":"Jovanovi\u0107","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.gendis.2022.03.004_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41568-019-0109-9","article-title":"Epigenetic therapy in immune-oncology","volume":"19","author":"Jones","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib16","doi-asserted-by":"crossref","first-page":"e1007362","DOI":"10.1371\/journal.pgen.1007362","article-title":"Cancer epigenetics: moving forward","volume":"14","author":"Nebbioso","year":"2018","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.gendis.2022.03.004_bib18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nrm3931","article-title":"50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond","volume":"16","author":"Verdin","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"10.1016\/j.gendis.2022.03.004_bib19","doi-asserted-by":"crossref","first-page":"a018762","DOI":"10.1101\/cshperspect.a018762","article-title":"Writers and readers of histone acetylation: structure, mechanism, and inhibition","volume":"6","author":"Marmorstein","year":"2014","journal-title":"Cold Spring Harbor Perspect Biol"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib20","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1002\/jcp.29415","article-title":"The epigenetic reader Brd4 is required for osteoblast differentiation","volume":"235","author":"Paradise","year":"2020","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.gendis.2022.03.004_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12864-016-2414-y","article-title":"Histone H4 acetylation and the epigenetic reader Brd4 are critical regulators of pluripotency in embryonic stem cells","volume":"17","author":"Gonzales-Cope","year":"2016","journal-title":"BMC Genom"},{"issue":"7","key":"10.1016\/j.gendis.2022.03.004_bib22","first-page":"396","article-title":"Chromatin: BRD4 kicks out nucleosomes with its HAT","volume":"17","author":"Strzyz","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.004_bib23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"issue":"31","key":"10.1016\/j.gendis.2022.03.004_bib24","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","article-title":"Blockade of oncogenic I\u03baB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors","volume":"111","author":"Ceribelli","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.gendis.2022.03.004_bib25","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1182\/blood-2013-08-522698","article-title":"c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells","volume":"123","author":"Roderick","year":"2014","journal-title":"Blood"},{"issue":"6390","key":"10.1016\/j.gendis.2022.03.004_bib26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.aat6664","article-title":"BRD4 and MYC\u2014clarifying regulatory specificity","volume":"360","author":"Sab\u00f2","year":"2018","journal-title":"Science"},{"issue":"25","key":"10.1016\/j.gendis.2022.03.004_bib27","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.7150\/thno.47432","article-title":"BET inhibitor suppresses melanoma progression via the noncanonical NF-\u03baB\/SPP1 pathway","volume":"10","author":"Deng","year":"2020","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.gendis.2022.03.004_bib28","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1158\/0008-5472.CAN-18-3177","article-title":"Inhibition of NF-\u03baB-dependent signaling enhances sensitivity and overcomes resistance to BET inhibition in uveal melanoma","volume":"79","author":"Ambrosini","year":"2019","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2022.03.004_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41419-018-0354-y","article-title":"Co-inhibition of BET proteins and NF-\u03baB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions","volume":"9","author":"Wu","year":"2018","journal-title":"Cell Death Dis"},{"issue":"50","key":"10.1016\/j.gendis.2022.03.004_bib30","doi-asserted-by":"crossref","first-page":"36094","DOI":"10.1074\/jbc.M113.485029","article-title":"Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor \u03baB (NF-\u03baB) signaling","volume":"288","author":"Wu","year":"2013","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib31","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ccell.2015.05.006","article-title":"Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy","volume":"27","author":"Stratikopoulos","year":"2015","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.gendis.2022.03.004_bib32","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1158\/1535-7163.MCT-20-0809","article-title":"Targeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma","volume":"20","author":"Shigeta","year":"2021","journal-title":"Mol Cancer Therapeut"},{"issue":"5","key":"10.1016\/j.gendis.2022.03.004_bib33","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1158\/1535-7163.MCT-18-1151","article-title":"Targeting the IGF1R\/PI3K\/AKT pathway sensitizes ewing sarcoma to BET bromodomain inhibitors","volume":"18","author":"Loganathan","year":"2019","journal-title":"Mol Cancer Therapeut"},{"issue":"11","key":"10.1016\/j.gendis.2022.03.004_bib34","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1158\/1078-0432.CCR-15-2389","article-title":"Molecular pathways: targeting the PI3K pathway in cancer-BET inhibitors to the rescue","volume":"22","author":"Stratikopoulos","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2022.03.004_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2019.11.017","article-title":"JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK\/STAT signalling pathway in ovarian cancer","volume":"126","author":"Bagratuni","year":"2020","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.gendis.2022.03.004_bib36","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1158\/1078-0432.CCR-16-0453","article-title":"The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.gendis.2022.03.004_bib37","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.gendis.2022.03.004_bib38","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1158\/0008-5472.CAN-18-1545","article-title":"SWI\/SNF-compromised cancers are susceptible to bromodomain inhibitors","volume":"79","author":"Shorstova","year":"2019","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.gendis.2022.03.004_bib39","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1158\/1078-0432.CCR-16-1658","article-title":"Identification of CCR2 and CD180 as robust pharmacodynamic tumor and blood biomarkers for clinical use with BRD4\/BET inhibitors","volume":"23","author":"Yeh","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.004_bib40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/1535-7163.MCT-16-0475","article-title":"HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of\u00a0BET family bromodomain inhibitors in tumors and surrogate tissues","volume":"16","author":"Lin","year":"2017","journal-title":"Mol Cancer Therapeut"},{"issue":"7327","key":"10.1016\/j.gendis.2022.03.004_bib41","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.gendis.2022.03.004_bib42","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2013-01-478420","article-title":"Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762","volume":"123","author":"Chaidos","year":"2014","journal-title":"Blood"},{"issue":"6241","key":"10.1016\/j.gendis.2022.03.004_bib43","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in\u00a0vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib44","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem Biol"},{"key":"10.1016\/j.gendis.2022.03.004_bib45","doi-asserted-by":"crossref","first-page":"107631","DOI":"10.1016\/j.pharmthera.2020.107631","article-title":"Targeting BET bromodomain proteins in cancer: the example of lymphomas","volume":"215","author":"Spriano","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.gendis.2022.03.004_bib46","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","article-title":"BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression","volume":"16","author":"Zhu","year":"2016","journal-title":"Cell Rep"},{"issue":"6282","key":"10.1016\/j.gendis.2022.03.004_bib47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.gendis.2022.03.004_bib48","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.gendis.2022.03.004_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2019.08.013","article-title":"BET protein targeting suppresses the PD-1\/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response","volume":"465","author":"Andrieu","year":"2019","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib50","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/cbin.11139","article-title":"JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression","volume":"43","author":"Liu","year":"2019","journal-title":"Cell Biol Int"},{"issue":"7","key":"10.1016\/j.gendis.2022.03.004_bib51","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.jid.2018.12.024","article-title":"BET inhibition modifies melanoma infiltrating T cells and enhances response to PD-L1 blockade","volume":"139","author":"Nikbakht","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"21","key":"10.1016\/j.gendis.2022.03.004_bib52","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1073\/pnas.1721559115","article-title":"Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors","volume":"115","author":"Lai","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/2326-6066.CIR-21-0224","article-title":"BET inhibition enhances TNF-mediated antitumor immunity","volume":"10","author":"Wellinger","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"10.1016\/j.gendis.2022.03.004_bib54","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/pcmr.12788","article-title":"The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner","volume":"32","author":"Erkes","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.gendis.2022.03.004_bib55","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.3389\/fimmu.2018.03104","article-title":"BET bromodomain inhibitors which permit treg function enable a combinatorial strategy to suppress GVHD in pre-clinical allogeneic HSCT","volume":"9","author":"Copsel","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib56","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12974-019-1511-7","article-title":"BET protein inhibition regulates cytokine production and promotes neuroprotection after spinal cord injury","volume":"16","author":"S\u00e1nchez-Ventura","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"7","key":"10.1016\/j.gendis.2022.03.004_bib57","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/0022034514534261","article-title":"BET inhibitor JQ1 blocks inflammation and bone destruction","volume":"93","author":"Meng","year":"2014","journal-title":"J Dent Res"},{"issue":"9","key":"10.1016\/j.gendis.2022.03.004_bib58","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2174\/1566524019666190126112238","article-title":"The bromodomain and extra-terminal protein inhibitor OTX015 suppresses T helper cell proliferation and differentiation","volume":"18","author":"Hu","year":"2018","journal-title":"Curr Mol Med"},{"issue":"11","key":"10.1016\/j.gendis.2022.03.004_bib59","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1084\/jem.20130376","article-title":"BET bromodomain inhibition suppresses TH17-mediated pathology","volume":"210","author":"Mele","year":"2013","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00262-020-02665-x","article-title":"Selective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses","volume":"70","author":"Remke","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"17","key":"10.1016\/j.gendis.2022.03.004_bib61","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/blood-2014-08-598037","article-title":"BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice","volume":"125","author":"Sun","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.gendis.2022.03.004_bib62","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.cell.2021.03.026","article-title":"BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection","volume":"184","author":"Mills","year":"2021","journal-title":"Cell"},{"issue":"7370","key":"10.1016\/j.gendis.2022.03.004_bib63","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.gendis.2022.03.004_bib64","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.exphem.2015.06.004","article-title":"BET bromodomain inhibitors in leukemia","volume":"43","author":"Basheer","year":"2015","journal-title":"Exp Hematol"},{"issue":"7370","key":"10.1016\/j.gendis.2022.03.004_bib65","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.004_bib66","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/leu.2013.338","article-title":"Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia","volume":"28","author":"Dawson","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.gendis.2022.03.004_bib67","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1535-7163.MCT-13-0770","article-title":"Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells","volume":"13","author":"Fiskus","year":"2014","journal-title":"Mol Cancer Therapeut"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.004_bib68","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ccell.2018.01.006","article-title":"Ezh2 and Runx1 mutations collaborate to initiate lympho-myeloid leukemia in early thymic progenitors","volume":"33","author":"Booth","year":"2018","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.gendis.2022.03.004_bib69","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1535-7163.MCT-14-0258","article-title":"BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD","volume":"13","author":"Fiskus","year":"2014","journal-title":"Mol Cancer Therapeut"},{"issue":"4","key":"10.1016\/j.gendis.2022.03.004_bib70","first-page":"1022","article-title":"A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia","volume":"106","author":"Lee","year":"2021","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib71","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/cam4.146","article-title":"BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1","volume":"2","author":"Stewart","year":"2013","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib72","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41467-020-20378-8","article-title":"BRD4-mediated repression of p53 is a target for combination therapy in AML","volume":"12","author":"Latif","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.gendis.2022.03.004_bib73","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.gendis.2022.03.004_bib74","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.gendis.2022.03.004_bib75","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1080\/10428194.2021.1881509","article-title":"A dose escalation study of RO6870810\/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"62","author":"Roboz","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"10.1016\/j.gendis.2022.03.004_bib76","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1002\/cncr.33590","article-title":"A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Borthakur","year":"2021","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.gendis.2022.03.004_bib77","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/1535-7163.MCT-21-0029","article-title":"Selective inhibition of the second bromodomain of BET family proteins results in robust antitumor activity in preclinical models of acute myeloid leukemia","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol Cancer Therapeut"},{"issue":"7570","key":"10.1016\/j.gendis.2022.03.004_bib78","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.gendis.2022.03.004_bib79","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fonc.2019.00016","article-title":"BRD4 inhibition enhances azacitidine efficacy in acute myeloid leukemia and myelodysplastic syndromes","volume":"9","author":"Pericole","year":"2019","journal-title":"Front Oncol"},{"issue":"40","key":"10.1016\/j.gendis.2022.03.004_bib80","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib81","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12935-021-01908-w","article-title":"BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting \u2018Undruggable\u2019 Myc-pathway genes","volume":"21","author":"Wu","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"10","key":"10.1016\/j.gendis.2022.03.004_bib82","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/leu.2017.10","article-title":"Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia","volume":"31","author":"Peirs","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.004_bib83","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/acs.jmedchem.6b01816","article-title":"Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins\u00a0with picomolar cellular potencies and capable of achieving tumor regression","volume":"61","author":"Zhou","year":"2018","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib84","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/s41375-019-0682-7","article-title":"The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment","volume":"34","author":"Kim","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib85","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-019-0761-2","article-title":"Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"24","key":"10.1016\/j.gendis.2022.03.004_bib86","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1002\/cncr.31646","article-title":"Double hit and double expressors in lymphoma: definition and treatment","volume":"124","author":"Riedell","year":"2018","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.gendis.2022.03.004_bib87","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/bloodadvances.2021004619","article-title":"Phase Ib study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma","volume":"5","author":"Dickinson","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.gendis.2022.03.004_bib88","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","article-title":"A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma","volume":"124","author":"Shapiro","year":"2021","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.gendis.2022.03.004_bib89","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.gendis.2022.03.004_bib90","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/s41375-021-01181-w","article-title":"BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma","volume":"35","author":"Fiskus","year":"2021","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.gendis.2022.03.004_bib91","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.3390\/cancers13195024","article-title":"RAS mediates BET inhibitor-endued repression of lymphoma migration and prognosticates a novel proteomics-based subgroup of DLBCL through its negative regulator IQGAP3","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.gendis.2022.03.004_bib92","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2015-04-639542","article-title":"Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.004_bib93","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/leu.2017.207","article-title":"BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against\u00a0mantle cell lymphoma cells","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.gendis.2022.03.004_bib94","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/leu.2014.106","article-title":"Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma","volume":"28","author":"Moros","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.gendis.2022.03.004_bib95","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.jid.2019.01.033","article-title":"Preclinical targeting of microRNA-214 in cutaneous T-cell lymphoma","volume":"139","author":"Kohnken","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib96","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00403-017-1749-9","article-title":"BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines","volume":"309","author":"Kamijo","year":"2017","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib97","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neo.2018.11.006","article-title":"Preclinical studies support combined inhibition of BET family proteins and histone deacetylases as epigenetic therapy for cutaneous T-cell lymphoma","volume":"21","author":"Zhao","year":"2019","journal-title":"Neoplasia"},{"issue":"10","key":"10.1016\/j.gendis.2022.03.004_bib98","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/bloodadvances.2020001756","article-title":"JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL","volume":"4","author":"Yumeen","year":"2020","journal-title":"Blood Adv"},{"issue":"7418","key":"10.1016\/j.gendis.2022.03.004_bib99","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib100","doi-asserted-by":"crossref","first-page":"12046","DOI":"10.1038\/s41598-018-30509-3","article-title":"Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma","volume":"8","author":"Tomska","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib101","doi-asserted-by":"crossref","first-page":"16495","DOI":"10.1038\/s41598-019-52714-4","article-title":"Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells","volume":"9","author":"Cortiguera","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.004_bib102","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/epi-2020-0189","article-title":"Epigenetic targeting of Waldenstr\u00f6m macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition","volume":"13","author":"Matissek","year":"2021","journal-title":"Epigenomics"},{"issue":"14","key":"10.1016\/j.gendis.2022.03.004_bib103","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/onc.2015.245","article-title":"Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors","volume":"35","author":"Gopalakrishnan","year":"2016","journal-title":"Oncogene"},{"issue":"48","key":"10.1016\/j.gendis.2022.03.004_bib104","doi-asserted-by":"crossref","first-page":"79637","DOI":"10.18632\/oncotarget.12876","article-title":"Therapeutic efficacy of the bromodomain inhibitor OTX015\/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes","volume":"7","author":"Boi","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.gendis.2022.03.004_bib105","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.gendis.2022.03.004_bib106","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1038\/sj.onc.1208447","article-title":"Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma","volume":"24","author":"Mattioli","year":"2005","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib107","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.gendis.2022.03.004_bib108","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bbrc.2017.01.088","article-title":"CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model","volume":"484","author":"Imayoshi","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.gendis.2022.03.004_bib109","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1042\/BSR20181245","article-title":"I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma","volume":"39","author":"Guo","year":"2019","journal-title":"Biosci Rep"},{"issue":"9","key":"10.1016\/j.gendis.2022.03.004_bib110","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1021\/acs.molpharmaceut.8b00554","article-title":"Potent activity of the bromodomain inhibitor OTX015 in multiple myeloma","volume":"15","author":"Shi","year":"2018","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.gendis.2022.03.004_bib111","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1021\/acs.molpharmaceut.8b00880","article-title":"The BET bromodomain inhibitor OTX015 synergizes with targeted agents in multiple myeloma","volume":"15","author":"Gu","year":"2018","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.gendis.2022.03.004_bib112","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41375-018-0044-x","article-title":"Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma","volume":"32","author":"Zhang","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232068","article-title":"Multiple myeloma: combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor","volume":"15","author":"Lim","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.gendis.2022.03.004_bib114","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41408-021-00545-w","article-title":"A phase 1b dose-escalation\/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma","volume":"11","author":"Ramasamy","year":"2021","journal-title":"Blood Cancer J"},{"issue":"26","key":"10.1016\/j.gendis.2022.03.004_bib115","doi-asserted-by":"crossref","first-page":"E2721","DOI":"10.1073\/pnas.1406722111","article-title":"BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma","volume":"111","author":"Bhadury","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib116","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PPO.0000000000000408","article-title":"BCL-2 inhibitors, present and future","volume":"25","author":"Ryan","year":"2019","journal-title":"Cancer J"},{"issue":"18","key":"10.1016\/j.gendis.2022.03.004_bib117","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.gendis.2022.03.004_bib118","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib119","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/hematology.2020000121","article-title":"Management of Waldenstr\u00f6m macroglobulinemia in 2020","volume":"2020","author":"Castillo","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"10.1016\/j.gendis.2022.03.004_bib120","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 inhibition in AML: an unexpected bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.gendis.2022.03.004_bib121","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/bloodadvances.2020002231","article-title":"BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression","volume":"4","author":"Cummin","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.gendis.2022.03.004_bib122","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1158\/0008-5472.CAN-16-1793","article-title":"Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies","volume":"77","author":"Bui","year":"2017","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.gendis.2022.03.004_bib123","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1021\/acs.jmedchem.0c00597","article-title":"A fast and clean BTK inhibitor","volume":"63","author":"Gabizon","year":"2020","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.gendis.2022.03.004_bib124","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"issue":"7","key":"10.1016\/j.gendis.2022.03.004_bib125","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs","volume":"21","author":"Boi","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.gendis.2022.03.004_bib126","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.celrep.2018.07.055","article-title":"BET inhibition-induced GSK3\u03b2 feedback enhances lymphoma vulnerability to PI3K inhibitors","volume":"24","author":"Derenzini","year":"2018","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.gendis.2022.03.004_bib127","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/biom10040501","article-title":"BET inhibitors synergize with carfilzomib to induce cell death in cancer cells via impairing Nrf1 transcriptional activity and exacerbating the unfolded protein response","volume":"10","author":"Vangala","year":"2020","journal-title":"Biomolecules"},{"issue":"36","key":"10.1016\/j.gendis.2022.03.004_bib128","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1038\/onc.2015.521","article-title":"BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells","volume":"35","author":"Muralidharan","year":"2016","journal-title":"Oncogene"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304222000733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304222000733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:34:32Z","timestamp":1762450472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304222000733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":128,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2352304222000733"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2022.03.004","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2022.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}]}}